한글목차

세계의 RNAi 기술 시장은 2025년에 31억 1,000만 달러로 추정되며, 2032년에는 82억 7,000만 달러에 달할 것으로 예측되며, 2025-2032년 CAGR은 15.0%로 성장할 전망입니다.

도표. 2025년 지역별 RNAi 기술 시장 점유율(%)

RNA 간섭 또는 RNAi는 단쇄 간섭 RNA(siRNA) 또는 마이크로 RNA(miRNA)에 의해 매개되는 유전자 침묵 과정을 말하며, RNAi는 유전자 발현의 선택적 억제와 기능적 유전체 스크리닝을 위한 강력한 툴로 부상하고 있습니다. RNAi는 선택적 유전자 발현 억제 및 기능 유전체학 스크리닝을 위한 강력한 툴로 등장했으며, 특정 질병 원인 유전자를 침묵시킴으로써 새로운 치료법을 개발할 수 있는 무한한 잠재력을 가지고 있습니다. 안전하고 효과적인 전달 시스템의 개발은 RNAi 치료법의 상용화에 더욱 기여할 것입니다. 바이오제약 기업 및 정부 기관의 RNAi 연구개발에 대한 막대한 투자로 강력한 제품 파이프라인이 생성되고 있습니다.

시장 역학

세계 RNAi 기술 시장의 성장을 주도하고 있는 것은 치료 분야 전반에 걸쳐 RNAi 기술의 치료 개발 적용 확대입니다. 현재 대사성 질환, 심혈관 질환, 신경 퇴행성 질환을 대상으로 하는 여러 의약품 후보물질이 임상시험 중에 있습니다. 강력한 제품 파이프라인과 새로운 RNAi 의약품의 진입으로 이 기술의 치료 가능성에 대한 낙관적인 전망이 확산되고 있습니다. 그러나 RNAi 전달의 기술적 문제와 오프 타깃 효과로 인해 시장 성장에 걸림돌이 될 수 있습니다. 또한 연구개발 인프라 구축과 임상 개발을 위해 많은 자본 투자가 필요하다는 점도 많은 소규모 기업의 발목을 잡고 있습니다. 지질 나노입자, 고분자 나노입자, 리간드 결합 분자와 같은 새로운 전달 시스템을 통해 전달 문제를 극복하기 위한 연구가 진행되고 있는 것은 시장 성장의 기회를 제공할 수 있습니다. 후기 임상시험에서 RNAi 기반 약물의 유망한 임상 결과는 시장 성장 기회를 제공할 수 있습니다.

본 조사의 주요 특징

• 세계의 RNAi 기술 시장을 상세하게 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 연평균 성장률(CAGR%)을 게재하고 있습니다.
• 또한 다양한 부문에 걸친 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 주요 인사이트를 제공합니다.
• 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 RNAi 기술 시장의 주요 기업을 프로파일링합니다.
• 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
• 세계 RNAi 기술 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 RNAi 기술 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 리포트 설명
  • 시장의 정의와 범위
• 개요
• COM(Coherent Opportunity Map)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회
• 영향 분석
• 시장 동향
• 규제 시나리오
• 인수와 제휴 시나리오
• 자금조달과 투자
• PEST 분석
• Porter의 산업 분석

제4장 세계의 RNAI 기술 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• 전체적인 영향
• 정부 구상
• 시장에 대한 COVID-19의 영향

제5장 세계의 RNAi 기술 시장, 용도별, 2020-2032년(10억 달러)

• 서론
• Drug Discovery 및 개발
• 치료
• 신경학
• 종양학
• 감염증
• 대사성 질환
• 기타
• 기능 유전체학
• 기타

제6장 세계의 RNAi 기술 시장, 최종사용자별, 2020-2032년(10억 달러)

• 서론
• 제약·바이오테크놀러지 기업
• 학술연구기관
• CRO와 CMO
• 기타

제7장 세계의 RNAi 기술 시장, 지역별, 2020-2032년(10억 달러)

• 서론
• 북미
• 라틴아메리카
• 유럽
• 아시아태평양
• 중동
• 아프리카

제8장 경쟁 구도

• 기업 개요
  • Alnylam Pharmaceuticals
  • OriGene Technologies, Inc.
  • Arrowhead Pharmaceuticals
  • Dicerna Pharmaceuticals
  • Silence Therapeutics
  • Ionis Pharmaceuticals
  • Merck & Co.
  • Qiagen NV
  • Thermo Fisher Scientific
  • Synlogic
  • Benitec Biopharma
  • Gradalis
  • Sirnaomics, Inc.
  • Marina BIoTech
  • Quark Pharmaceuticals
  • Regulus Therapeutics
  • GeneCare Research Institute Co., Ltd.
  • ASC Therapeutics
• 운명의 수레바퀴
• COM(Coherent Opportunity Map)

제9장 참고 문헌과 조사 방법

• 참고 문헌
• 조사 방법

영문목차

Global Rnai Technology Market is estimated to be valued at USD 3.11 Bn in 2025 and is expected to reach USD 8.27 Bn by 2032, growing at a compound annual growth rate (CAGR) of 15.0% from 2025 to 2032.

Figure. Rnai Technology Market Share (%), By Region 2025

Global RNAi technology market growth is driven by growing applications of RNA interference technology in therapeutics development and research. RNA interference or RNAi refers to the process of gene silencing mediated by short interfering RNAs (siRNAs) or microRNAs (miRNAs). It has emerged as a powerful tool for selective inhibition of gene expression and functional genomics screens. RNAi holds immense potential for developing novel therapeutics by silencing specific disease-causing genes. The development of safe and effective delivery systems further contributes to the commercialization of RNAi-based therapies. Significant investments in RNAi research and development from biopharma companies and government organizations are resulting in a strong product pipeline.

Market Dynamics:

Global RNAi technology market growth is driven by increasing applications of RNAi technology for developing treatments across therapeutic areas. Several drug candidates targeting metabolic, cardiovascular and neurodegenerative disorders are currently under clinical trials. The strong product pipeline and entry of novel RNAi drugs are creating high optimism around the therapeutic potential of this technology. However, technical challenges in RNAi delivery and off-target effects can hamper the market growth. Moreover, requirement of high capital investments for building R&D infrastructure and clinical development deters many small companies. Ongoing research on overcoming the delivery challenges through novel delivery systems such as lipid nanoparticles, polymeric nanoparticles and ligand-conjugated molecules can offer market growth opportunities. Promising clinical outcomes of RNAi-based drugs in late-stage trials can offer market growth opportunities.

Key Features of the Study:

• This report provides in-depth analysis of the global RNAi technology market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global RNAi technology market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Mirna Therapeutics, and Quark Pharmaceuticals
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global RNAi technology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global RNAi technology market

Detailed Segmentation-

• By Application
  • Drug Discovery and Development
  • Therapeutics
  • Neurology
  • Oncology
  • Infectious Diseases
  • Metabolic Diseases
  • Others
  • Functional Genomics
  • Other
• By End User
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • CROs & CMOs
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Alnylam Pharmaceuticals
  • OriGene Technologies, Inc.
  • Arrowhead Pharmaceuticals
  • Dicerna Pharmaceuticals
  • Silence Therapeutics
  • Ionis Pharmaceuticals
  • Merck & Co.
  • Qiagen N.V.
  • Thermo Fisher Scientific
  • Synlogic
  • Benitec Biopharma
  • Gradalis
  • Sirnaomics, Inc.
  • Marina Biotech
  • Quark Pharmaceuticals
  • Regulus Therapeutics
  • GeneCare Research Institute Co., Ltd.
  • ASC Therapeutics

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Application
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Rnai Technology Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global RNAi Technology Market, By Application, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Drug Discovery and Development
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Therapeutics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Neurology
• Oncology
• Infectious Diseases
• Metabolic Diseases
• Others
• Functional Genomics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global RNAi Technology Market, By End User, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Pharmaceutical & Biotechnology Companies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Academic & Research Institutes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• CROs & CMOs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global RNAi Technology Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Company Profiles
  • Alnylam Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • OriGene Technologies, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Arrowhead Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Dicerna Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Silence Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Ionis Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Qiagen N.V.
  • Thermo Fisher Scientific
  • Synlogic
  • Benitec Biopharma
  • Gradalis
  • Sirnaomics, Inc.
  • Marina Biotech
  • Quark Pharmaceuticals
  • Regulus Therapeutics
  • GeneCare Research Institute Co., Ltd.
  • ASC Therapeutics
• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

9. References and Research Methodology

• References
• Research Methodology
• About Us and Sales Contact